查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1778884

學名藥市場 - 全球行業規模、佔有率、趨勢、機會和預測，按類型、按應用、按藥物輸送、按形式、按來源、按配銷通路、按地區和競爭進行細分，2020-2030 年

Generic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Drug Delivery, By Form, By Source, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球學名藥市場價值為 4,434.4 億美元，預計在預測期內將穩定成長，到 2030 年的複合年成長率為 6.27%。全球學名藥市場主要受幾個關鍵因素驅動，包括慢性病盛行率上升、醫療保健成本增加以及對負擔得起的治療方案的需求。學名藥提供了一種比品牌藥更具成本效益的替代品，使其更易於被更多人使用。品牌藥的專利到期為學名藥製造商進入市場創造了機會，從而加劇了競爭並降低了價格。政府提倡使用學名藥以降低醫療保健支出的措施進一步推動了市場成長。對學名藥的需求不斷成長以及新興市場學名藥生產能力的擴張也促進了市場的擴張。在可負擔性、可近性和市場競爭的推動下，全球學名藥市場可望持續成長。學名藥和生物相似藥僅占美國醫療保健總支出的 1.2%，凸顯了它們的成本效益。

市場概覽
預測期 2026-2030
2024年市場規模 4434.4億美元
2030年市場規模 6408.8億美元
2025-2030 年複合年成長率 6.27%
成長最快的領域 小分子學名藥
最大的市場 北美洲

關鍵市場促進因素

成本效益和可負擔性

主要市場挑戰

監管障礙和核准流程

主要市場趨勢

仿製生物製劑（生物相似藥）的進展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球學名藥市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型（小分子學名藥和生物學名藥）
    • 按應用（心血管疾病、糖尿病、神經病學、腫瘤學、抗發炎疾病、其他）
    • 透過藥物輸送（口服、外用、腸外、其他）
    • 按劑型（片劑、膠囊、注射劑、其他）
    • 按來源（內部和合約製造組織）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美學名藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲學名藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太學名藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美洲學名藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲學名藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Aurobindo Pharma Limited
  • Dr Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Novo Nordisk A/S
  • Abbott Laboratories Inc.
  • Endo International plc
  • Sanofi SA
  • Aspen Pharmacare Holdings Limited
  • Lupin Limited

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 7332

Global Generic Drugs Market was valued at USD 443.44 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 6.27% through 2030. The Global Generic Drugs Market is primarily driven by several key factors, including the rising prevalence of chronic diseases, increasing healthcare costs, and the need for affordable treatment options. Generic drugs offer a cost-effective alternative to brand-name medications, making them accessible to a broader population. Patent expirations of branded drugs create opportunities for generic manufacturers to enter the market, leading to increased competition and lower prices. Government initiatives promoting the use of generic drugs to reduce healthcare expenditures further fuel market growth. The growing demand for generic versions of biologic drugs and the expansion of generic drug manufacturing capabilities in emerging markets also contribute to the market's expansion. The Global Generic Drugs Market is poised for sustained growth driven by affordability, accessibility, and market competition. Generics and biosimilars represent just 1.2% of total U.S. healthcare spending, underscoring their cost-effectiveness.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 443.44 Billion
Market Size 2030USD 640.88 Billion
CAGR 2025-20306.27%
Fastest Growing SegmentSmall Molecule Generics
Largest MarketNorth America

Key Market Drivers

Cost-effectiveness and Affordability

The affordability and accessibility of generic drugs compared to their brand-name counterparts constitute a pivotal factor driving their widespread adoption and market expansion on a global scale. Generic medications, renowned for their lower price points, serve as indispensable alternatives for patients and healthcare systems grappling with constrained budgets or exorbitant out-of-pocket expenses associated with branded pharmaceuticals. In regions where healthcare resources are scarce or where patients bear a substantial burden of medication costs, the cost-effectiveness of generic drugs emerges as a cornerstone of healthcare provision. The considerable price differentials between generic and brand-name medications facilitate broader access to essential treatments, ensuring that individuals can afford the medications they need to manage their health conditions effectively.

A fundamental driver of the cost-effectiveness of generic drugs lies in the expiration of patents on brand-name medications. Upon patent expiry, generic manufacturers gain the legal right to produce and distribute equivalent versions of the drug, igniting competition within the pharmaceutical market. This competitive landscape fosters price reductions as generic manufacturers leverage economies of scale, streamlined production processes, and reduced research and development costs to offer their products at significantly lower prices.

Key Market Challenges

Regulatory Hurdles and Approval Processes

One of the primary challenges confronting the Global Generic Drugs Market is navigating the complex regulatory landscape governing generic drug approval processes. Regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, enforce stringent standards and requirements for the approval of generic medications. Generic manufacturers must demonstrate bioequivalence, pharmaceutical equivalence, and therapeutic equivalence to the reference brand-name drug through comprehensive analytical and clinical studies. The regulatory pathway for generic drug approval often entails navigating intricate legal frameworks, conducting extensive pharmacokinetic and pharmacodynamic studies, and adhering to stringent quality assurance standards, all of which pose formidable barriers to entry for manufacturers. Disparities in regulatory requirements between different regions and countries necessitate meticulous compliance with diverse regulatory mandates, adding complexity and uncertainty to the generic drug approval process.

Key Market Trends

Advancements in Generic Biologics (Biosimilars)

The emergence of biosimilars heralds a transformative paradigm shift within the pharmaceutical landscape, ushering in a new era of accessibility, affordability, and innovation in biologic drug therapy. Biosimilars, colloquially referred to as generic versions of biologic drugs, constitute a rapidly burgeoning segment of the generic drugs market, poised to revolutionize the treatment landscape across a diverse array of therapeutic domains. This paradigmatic evolution is underpinned by significant advancements in biotechnology and regulatory frameworks governing biosimilar approval, which collectively catalyze the development, commercialization, and widespread adoption of biosimilar therapies as compelling alternatives to their costly brand-name counterparts. In 2023, the average out-of-pocket cost for a generic drug was USD 7.05, compared to $27.10 for a brand-name drug.

The ascendancy of biosimilars as a burgeoning force within the generic drugs market is predicated upon the intricate interplay between scientific innovation and regulatory harmonization. Pioneering breakthroughs in biotechnological methodologies have empowered manufacturers to elucidate the complex structural and functional attributes of biologic drugs with unparalleled precision and fidelity, thereby facilitating the rational design and engineering of biosimilar formulations that closely mimic the reference biologic products. Leveraging state-of-the-art analytical techniques, manufacturers can meticulously characterize the physicochemical properties, pharmacokinetic profiles, and immunogenicity profiles of biosimilars, ensuring their comparability to the reference biologic drugs with utmost rigor and scientific rigor.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Aurobindo Pharma Limited
  • Dr Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Novo Nordisk A/S
  • Abbott Laboratories Inc.
  • Endo International plc
  • Sanofi S.A.
  • Aspen Pharmacare Holdings Limited
  • Lupin Limited

Report Scope:

In this report, the Global Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Generic Drugs Market, By Type:

  • Small Molecule Generics
  • Biosimilars

Generic Drugs Market, By Application:

  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Oncology
  • Anti-Inflammatory Diseases
  • Others

Generic Drugs Market, By Drug Delivery:

  • Oral
  • Topical
  • Parenteral
  • Others

Generic Drugs Market, By Form:

  • Tablet
  • Capsule
  • Injection
  • Others

Generic Drugs Market, By Source:

  • In House
  • Contract Manufacturing Organizations

Generic Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Generic Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Generic Drugs Market.

Available Customizations:

Global Generic Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Small Molecule Generics and Biosimilars)
    • 5.2.2. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
    • 5.2.3. By Drug Delivery (Oral, Topical, Parenteral, Others)
    • 5.2.4. By Form (Tablet, Capsule, Injection, Others)
    • 5.2.5. By Source (In House and Contract Manufacturing Organizations)
    • 5.2.6. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2024)
  • 5.3. Market Map

6. North America Generic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Drug Delivery
    • 6.2.4. By Form
    • 6.2.5. By Source
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Generic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Drug Delivery
        • 6.3.1.2.4. By Form
        • 6.3.1.2.5. By Source
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Canada Generic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Drug Delivery
        • 6.3.2.2.4. By Form
        • 6.3.2.2.5. By Source
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Mexico Generic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Drug Delivery
        • 6.3.3.2.4. By Form
        • 6.3.3.2.5. By Source
        • 6.3.3.2.6. By Distribution Channel

7. Europe Generic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Drug Delivery
    • 7.2.4. By Form
    • 7.2.5. By Source
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Generic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Drug Delivery
        • 7.3.1.2.4. By Form
        • 7.3.1.2.5. By Source
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. United Kingdom Generic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Drug Delivery
        • 7.3.2.2.4. By Form
        • 7.3.2.2.5. By Source
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. Italy Generic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Drug Delivery
        • 7.3.3.2.4. By Form
        • 7.3.3.2.5. By Source
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. France Generic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Drug Delivery
        • 7.3.4.2.4. By Form
        • 7.3.4.2.5. By Source
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Generic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Drug Delivery
        • 7.3.5.2.4. By Form
        • 7.3.5.2.5. By Source
        • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Generic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Drug Delivery
    • 8.2.4. By Form
    • 8.2.5. By Source
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Generic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Drug Delivery
        • 8.3.1.2.4. By Form
        • 8.3.1.2.5. By Source
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. India Generic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Drug Delivery
        • 8.3.2.2.4. By Form
        • 8.3.2.2.5. By Source
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. Japan Generic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Drug Delivery
        • 8.3.3.2.4. By Form
        • 8.3.3.2.5. By Source
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. South Korea Generic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Drug Delivery
        • 8.3.4.2.4. By Form
        • 8.3.4.2.5. By Source
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Generic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Drug Delivery
        • 8.3.5.2.4. By Form
        • 8.3.5.2.5. By Source
        • 8.3.5.2.6. By Distribution Channel

9. South America Generic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Drug Delivery
    • 9.2.4. By Form
    • 9.2.5. By Source
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Generic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Drug Delivery
        • 9.3.1.2.4. By Form
        • 9.3.1.2.5. By Source
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. Argentina Generic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Drug Delivery
        • 9.3.2.2.4. By Form
        • 9.3.2.2.5. By Source
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Colombia Generic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Drug Delivery
        • 9.3.3.2.4. By Form
        • 9.3.3.2.5. By Source
        • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Generic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Drug Delivery
    • 10.2.4. By Form
    • 10.2.5. By Source
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Generic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Drug Delivery
        • 10.3.1.2.4. By Form
        • 10.3.1.2.5. By Source
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Saudi Arabia Generic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Drug Delivery
        • 10.3.2.2.4. By Form
        • 10.3.2.2.5. By Source
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. UAE Generic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Drug Delivery
        • 10.3.3.2.4. By Form
        • 10.3.3.2.5. By Source
        • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Sandoz International GmbH
  • 14.3. Viatris Inc.
  • 14.4. Sun Pharmaceutical Industries Ltd.
  • 14.5. Fresenius Kabi AG
  • 14.6. STADA Arzneimittel AG
  • 14.7. Aurobindo Pharma Limited
  • 14.8. Dr Reddy's Laboratories Ltd.
  • 14.9. Cipla Ltd.
  • 14.10. Novo Nordisk A/S
  • 14.11. Abbott Laboratories Inc.
  • 14.12. Endo International plc
  • 14.13. Sanofi S.A.
  • 14.14. Aspen Pharmacare Holdings Limited
  • 14.15. Lupin Limited

15. Strategic Recommendations

16. About Us & Disclaimer